CNSY:NASDAQ
Cerenome, Inc.
$2.32
arrow_downward
-2.72%(-0.065) 1D
$2.35
arrow_upward
+1.08% (+0.025)bedtimeAfter hours
Closed: Sep 11, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CNSY...
Open
$2.40
High
$2.49
Low
$2.31
Mkt. cap
17.65M
Avg. vol.
71.48K
Volume
79.23K
52-wk high
$4.16
52-wk low
$2.31
EPS
-$4.42
Beta
1.39
Shares outstanding
7.59M
No. of employees
28
Open
$2.40
High
$2.49
Low
$2.31
Mkt. cap
17.65M
Avg. vol.
71.48K
Volume
79.23K
52-wk high
$4.16
52-wk low
$2.31
EPS
-$4.42
Beta
1.39
Shares outstanding
7.59M
No. of employees
28
News stories
From web sources and news partners
Benzinga
·
10 hours ago
ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday
GuruFocus
·
11 hours ago
CNSY Maintains Buy Rating -- Price Target Lowered to $43.00 by Ascendiant Capital
AllSci
·
14 hours ago
Cerenome secures USD 20m royalty-based financing to scale CNSide diagnostics platform
Investing.com Canada
·
1 day ago
Form 8K Cerenome, Inc For: 10 September By Investing.com
Profile
Cerenome, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Cerenome, Inc.